Department of Epidemiology and Preclinical Research, L. Spallanzani National Institute for Infectious Diseases (INMI), Rome, Italy.
BMC Infect Dis. 2010 Nov 22;10:333. doi: 10.1186/1471-2334-10-333.
Blood cytokines and chemokines have been proposed as biomarkers for tuberculosis (TB). Recently, some immune mediators found in the urine of patients with renal dysfunctions have also been suggested as potential biomarkers. Finding biomarkers for TB in urine would present several advantages over blood in terms of collection and safety. The objective of this study was to investigate the presence of cytokines and chemokines in the urine of patients with pulmonary TB at the time of diagnosis. In a subgroup, the evaluation was also performed during TB treatment and at therapy completion. Patients with lung diseases other than TB, and healthy subjects were also enrolled.
Urine samples from 138 individuals, after exclusion of renal dysfunctions, were collected during an 18 month-period. Among them, 58 received a diagnosis of pulmonary TB, 28 resulted having lung diseases other than TB, and 34 were healthy subjects. Moreover, 18 TB patients, 9 of whom were tested 2 months after AFB smear sputum reversion and 9 of whom were cured of TB were also included. Cytokines and chemokines in urine were evaluated using a Cytometric-Bead-Array-Flex-Set. IP-10 detection in 49 subjects was also carried out in parallel by using an Enzyme Linked ImmunoSorbent Assay (ELISA).
IFN-γ, TNF-α, IL-2, IL-8, MIP-1α, MIP-1β and RANTES were poorly detected in all urine samples. Conversely, IP-10 was consistently detected in urine and its level was significantly increased in patients with lung disease compared to healthy subjects (p < 0.001). Increased IP-10 levels were found in both pulmonary TB and lung diseases other than TB. Moreover lower IP-10 levels were found in cured-TB patients compared to the levels at the time of diagnosis, and this difference was close to significance (p = 0.06). Interestingly, we demonstrated a significant correlation between the data obtained by flow cytometry and ELISA (r² 0.82, p < 0.0001).
IP-10, in contrast to IFN-γ, TNF-α, IL-2, IL-8, MIP-1α, MIP-1β and RANTES, is detectable in the urine of patients with pulmonary diseases in the absence of renal dysfunctions. Moreover, the IP-10 level in cured-TB patients is comparable to that found in healthy subjects. More studies are needed to further investigate the clinical utility of these findings.
血液细胞因子和趋化因子已被提出作为结核病 (TB) 的生物标志物。最近,在肾功能障碍患者的尿液中发现的一些免疫介质也被认为是潜在的生物标志物。与血液相比,在尿液中寻找 TB 标志物在采集和安全性方面具有多项优势。本研究的目的是在诊断时检测肺结核患者尿液中的细胞因子和趋化因子的存在。在一个亚组中,还在 TB 治疗期间和治疗完成时进行了评估。还招募了患有非 TB 肺部疾病的患者和健康受试者。
在 18 个月的时间内,收集了排除肾功能障碍的 138 个人的尿液样本。其中,58 人被诊断为肺结核,28 人患有非 TB 肺部疾病,34 人是健康受试者。此外,还纳入了 18 名 TB 患者,其中 9 名在 AFB 痰涂片反转后 2 个月进行了检测,9 名治愈了 TB。使用流式细胞术微珠阵列试剂盒评估尿液中的细胞因子和趋化因子。在 49 名受试者中还平行使用酶联免疫吸附试验 (ELISA) 检测 IP-10。
所有尿液样本中均未检测到 IFN-γ、TNF-α、IL-2、IL-8、MIP-1α、MIP-1β 和 RANTES。相反,IP-10 始终在尿液中检测到,与健康受试者相比,肺病患者的 IP-10 水平显着升高(p < 0.001)。在肺结核和非肺结核中均发现 IP-10 水平升高。此外,与诊断时相比,治愈的 TB 患者的 IP-10 水平较低,且差异接近显着(p = 0.06)。有趣的是,我们证明了流式细胞术和 ELISA 获得的数据之间存在显着相关性(r² 0.82,p < 0.0001)。
与 IFN-γ、TNF-α、IL-2、IL-8、MIP-1α、MIP-1β 和 RANTES 相比,IP-10 可在无肾功能障碍的肺病患者的尿液中检测到。此外,治愈的 TB 患者的 IP-10 水平与健康受试者相当。需要进一步研究这些发现的临床实用性。